Research and Markets: Thought Leader Insight & Analysis Report - Crohns Disease, Ulcerative Colitis Q1 2010 Out Now

DUBLIN--(BUSINESS WIRE)--Research and Markets(http://www.researchandmarkets.com/research/2efd5f/thought_leader_ins) has announced the addition of the "Thought Leader Insight & Analysis Report - Crohns Disease, Ulcerative Colitis Q1 2010" report to their offering.

“Thought Leader Insight & Analysis Report - Crohns Disease, Ulcerative Colitis Q1 2010”

In this last Gastroenterology Thought Leader Panel the publisher reported on key unmet needs in the treatment of Crohns disease and ulcerative colitis. In this report the publisher asks six internationally recognized experts in the treatment of inflammatory bowel disease to build on that, and engage with us in a thought exercise with the aim of ranking the most medically valuable initiatives in the developmental pipeline. Each thought leader was asked to identify the five agents that they were most looking forward to having available in the next few years - their Fantasy Formulary.

The Panel then turns to the more immediately commercially relevant question of comparing Simponi to other anti-TNF agents, next generation inhibitors of leukocyte trafficking to natalizumab and to each other, and both of these classes to p40 approaches.

The Panel was well represented by both very aggressive treaters, looking for stem cell transplants for everybody, and the very conservative treater who is looking to replace (whenever possible) biologicals and immunomodulators with more natural, homeopathic medicines. Each side makes their case.

Finally, Panelists comment on recent clinical setbacks for Humira in ulcerative colitis, and thoughts on Cimzia, 5-ASA products, new steroids, probiotics, oral small molecules (tasocitinib, apremilast, others) and newer biological approaches (e.g. IL-17, innate immunostimulators).

Key Topics Covered:

• Fantasy Formulary Survey Methodology
• Mucosal Healing / Antifibrotic
• Reduce Serious Adverse Events
• Diagnostics
• New Therapeutic Approaches
• Tysabri (natalizumab; Biogen / Elan)
• vedolizumab (MLN-02 / MLN-0002; Takeda)
• rhuMAb-b7 (Genentech)
• PF-00547659 (Pfizer)
• Stelara (ustekinumab / CNTO-1275; Centocor/Janssen-Cilag)
• briakinumab (ABT-874; Abbott)
• dual p40 / p19 MAb (IL-23 selective MAb; Merck / Schering-Plough)
• Prochymal (Osiris Therapeutics)
• PDA-001; Celgene Cellular Therapeutics
• Remicade (infliximab; Centocor)
• Humira (adalimumab; Abbott)
• Cimzia (certolizumab; UCB)
• Simponi; golimumab (Centocor / Schering-Plough / Merck)
• COLAL-PRED; prednisolone sodium metasulfobenzoate (Alizyme)
• Entocort; budesonide (Cosmo/Santarus)
• Probiotics
• AIN-457 (Novartis)
• tasocitinib; CP-690550 (Pfizer)
• Diet / Gluten Free
• Leukine; sargramostin; GMCSF (Bayer-Schering)
• Traficet-EN (CCX-282-B; ChemoCentryx/GSK)
• Asacol / Asacol-HD (Warner-Chilcott)
• Apriso (mesalamine; Salix)
• Lialda (mesalamine; Shire)
• Thought-Leader Interviews

For more information visit http://www.researchandmarkets.com/research/2efd5f/thought_leader_ins.